Today: August 31, 2015, 10:51 am

SADIF Analytics releases new summary due diligence report for Biostar Pharmaceuticals Inc (BSPM)

SADIF-Investment Analytics has applied its StockMarks™ stock-rating system to Biostar Pharmaceuticals Inc (BSPM) and produced a report, rating the company's attractiveness to long-term investors. 2014-03-13 12:29:57
Ilhavo, Portugal - SADIF Investment Analytics, announces a new summary due diligence report covering Biostar Pharmaceuticals Inc (BSPM). The report uses SADIF's powerful StockMarks™ stock rating system and contains important analysis for any current or potential Biostar Pharmaceuticals Inc investor.

Report Summary: Biostar Pharmaceuticals Inc is a low quality company with a negative outlook. Biostar Pharmaceuticals Inc has weak business growth and is run by mediocre management. The trend in Biostar Pharmaceuticals Inc fair value exchange rate against its closest rated-competitor, SurModics, Inc., has been depreciating over the past 2 weeks. When compared to its closest competitor, Biostar Pharmaceuticals Inc shows similar overvaluation and is equally likely to underperform the market.

The report breaks down the Total StockMark into its three components - business, management and price, performing an in-depth analysis of Biostar Pharmaceuticals Inc for long-term investors.
The report has been distributed to Thomson Reuters. It is available in Investext and from multiple professional platforms including Thomson Research, Thomson ONE Banker, DIALOG/INTELLISCOPE, Thomson Gale, One source West Services, and Dow Jones/Factiva.

About SADIF-Investment Analytics:
SADIF-Investment Analytics is an independent investment research company covering 31 different markets and over 22,000 companies. The StockMarks rating system is based on proven investment principles and is designed to drive long-term shareholder returns.

Press Information
SADIF - Investment Analytics
SADIF - Investment Analytics
Rua Domingos F. Pinto Basto, 21
3830-176 Ilhavo, Portugal

António Mendes
(+351) 234 296930

Published by
Antonio Mendes
(+351) 234 322 037
Related Articles

Disclaimer: If you have any questions regarding information in this press release please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims the content included in this release.